Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Dahaba, AA; Mueller, G; Mattiassich, G; Rumpold-Seitlinger, G; Bornemann, H; Rehak, PH; Linck, G; Mischinger, HJ; Metzler, H.
Effect of somatostatin analogue octreotide on pain relief after major abdominal surgery.
Eur J Pain. 2009; 13(8): 861-864.
Doi: 10.1016/j.ejpain.2008.10.006
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Co-Autor*innen der Med Uni Graz
- Bornemann-Cimenti Helmar
- Metzler Helfried
- Mischinger Hans-Jörg
- Rehak Peter
- Rumpold-Seitlinger Gudrun
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Octreotide acetate is an 8-amino-acids synthetic octapeptide analogue of somatostatin with much-enhanced duration of action and lower incidence of side effects. We assessed the utility of using intravenous octreotide as an adjuvant to opioid analgesia that might exert a post-operative opioid-sparing effect. Methods: Forty-four patients were randomly allocated, to receive either a placebo or intraoperative octreotide 0.33 mu g kg(-1) h(-1) intravenous infusion that was maintained in the post-operative period. Patients received for post-operative analgesia an intravenous piritramide patient controlled analgesia (PCA), set to deliver a piritramide 0.02 mg kg(-1) dose. Results: Two-way ANOVA revealed significantly fewer (P = 0.0003) mean +/- SD weighted piritramide dose requirements in the octreotide group (19.5 +/- 6.3 mu g kg(-1) h(-1)) than in the control group (35.7 +/- 8.2 mu g kg(-1) h(-1)). Dunnett's two-sided multiple-comparison post hoc test revealed a significant difference between the two groups during the first 22 post-operative hours, following which there were no differences between the two groups. There were no significant differences over time in the mean arterial pressure (P = 0.722), heart rate (P = 0.579) and respiratory rate (P = 0.823) between the octreotide group (80 +/- 10 mm Hg, 74 +/- 12, 14 +/- 2) and the control group (82 +/- 9 mm Hg, 76 +/- 11, 15 +/- 3), respectively. Conclusion: We demonstrated that perioperative octreotide intravenous infusion could be an adjuvant to opioid analgesia as it exerted a piritramide opioid-sparing effect. We encountered more systemic side effects such as nausea, abdominal discomfort, and diarrhea in the octreotide group than in the control group. Our findings could be beneficial to patients who cannot tolerate the adverse effects of opioids. (C) 2008 European Federation of Chapters of the International Association for the Study of Pain. Published by Elsevier Ltd. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Abdomen - surgery
- Aged -
- Analgesia, Patient-Controlled -
- Analgesics, Opioid - administration and dosage Analgesics, Opioid - therapeutic use
- Analysis of Variance -
- Female -
- GABA Modulators - therapeutic use
- Hemodynamics - drug effects
- Humans -
- Infusions, Intravenous -
- Male -
- Midazolam - therapeutic use
- Middle Aged -
- Octreotide - adverse effects Octreotide - therapeutic use
- Pain, Postoperative - drug therapy
- Pirinitramide - administration and dosage Pirinitramide - therapeutic use
- Postoperative Nausea and Vomiting - complications Postoperative Nausea and Vomiting - epidemiology
- Find related publications in this database (Keywords)
- Post-operative pain
- Post-operative analgesia
- Patient controlled analgesia
- Octreotide